Compare Abbott Laboratories (ABT) vs NetApp Inc. (NTAP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs NetApp Inc. — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while NetApp Inc. trades at $164.68 (market cap $32.48B). The key difference: Abbott Laboratories is far larger — about 5.1× NetApp Inc.'s market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | NTAP | |
|---|---|---|
Market Cap | $166.94B | $32.48B |
Sector | Health | Technology |
52-Week High | $136.62 | $181.08 |
52-Week Low | $82.57 | $94.11 |
Enterprise Value | $193.69B | $31.63B |
Dividend Yield | 2.63% | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
NTAP trades at $165.78, up 7.53% in the last session, near its consensus price target of $167.45. The stock shows strong momentum with three consecutive quarterly earnings beats and bullish technical signals from moving averages. Revenue grew to $6.57B in 2025 with an 18.43% net income margin, while cash flow turned positive at $840M. Recent news highlights AI-driven growth opportunities and strategic partnerships enhancing its data infrastructure offerings.
The outlook remains positive given AI demand tailwinds and solid execution, though valuation multiples are elevated. Key risks include competitive pressures and reliance on enterprise spending cycles. Analyst consensus leans neutral with a slight buy bias, suggesting cautious optimism for further upside if growth sustains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →
